Evidence map›Paper›PMID 27819679›Full record

ArticleOncogene2017

ZNF750 is a lineage-specific tumour suppressor in squamous cell carcinoma.

M Hazawa, D-C Lin, H Handral, L Xu, Y Chen, Y-Y Jiang, A Mayakonda, L-W Ding, X Meng, A Sharma and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. ZNF750: A Novel Prognostic Biomarker in Metastatic Prostate Cancer.International journal of molecular sciences · 2023
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

M HazawaCancer Science Institute of Singapore, National University of Singapore, Singapore.
D-C LinCancer Science Institute of Singapore, National University of Singapore, Singapore.
H HandralDepartment of Oral and Maxillofacial Surgery, Faculty of Dentistry, National University of Singapore, Singapore.
L XuCancer Science Institute of Singapore, National University of Singapore, Singapore.
Y ChenCancer Science Institute of Singapore, National University of Singapore, Singapore.
Y-Y JiangCancer Science Institute of Singapore, National University of Singapore, Singapore.
A MayakondaCancer Science Institute of Singapore, National University of Singapore, Singapore.
L-W DingCancer Science Institute of Singapore, National University of Singapore, Singapore.
X MengCancer Science Institute of Singapore, National University of Singapore, Singapore.
A SharmaCancer Science Institute of Singapore, National University of Singapore, Singapore.
S SamuelCancer Science Institute of Singapore, National University of Singapore, Singapore.
M M MovahedniaDepartment of Oral and Maxillofacial Surgery, Faculty of Dentistry, National University of Singapore, Singapore.
R W WongCell-Bionomics Research Unit, Innovative Integrated Bio-Research Core, Institute for Frontier Science Initiative, Kanazawa University, Kanazawa, Japan.
H YangCancer Science Institute of Singapore, National University of Singapore, Singapore.
C TongDepartment of Oral and Maxillofacial Surgery, Faculty of Dentistry, National University of Singapore, Singapore.
H P KoefflerCancer Science Institute of Singapore, National University of Singapore, Singapore.

Funding

Pilot and Feasibility ProgramP30DK041301 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ROZENGURT, JUAN ENRIQUE · 1990 to 2019
$18.0M
NIDDK NIH HHS P30 DK041301
6 · The paper itself

Abstract

ZNF750 controls epithelial homeostasis by regulating epidermal-differentiation genes, a role underscored by its pathogenic mutations in esophageal squamous cell cancers (SCCs). However, the precise role of ZNF750 in SCC cell biology remains unclear. In this study, we report that ZNF750 is exclusively deleted, mutated and underexpressed in human SCCs, and low ZNF750 expression is associated with poor survival. Restoration of wildtype, but not mutant ZNF750 protein uniquely inhibited the malignant phenotypes of SCC cells both in vitro and in vivo. Notably, ZNF750 promoted the expression of a long non-coding RNA (TINCR), which mediated both cancer-inhibition and differentiation-induction effects of ZNF750. In addition, ZNF750 potently suppressed cell migration by directly inhibiting the transactivation of LAMC2. Together, our findings characterize ZNF750 as a crucial SCC-specific suppressor and uncover its novel anticancer-associated functions.

Indexed as

Genes, Tumor SuppressorAnimalsCarcinoma, Squamous CellCell DifferentiationCell LineageCell Line, TumorCell MovementDNA, NeoplasmEsophageal NeoplasmsFemaleGene DeletionGene Expression Regulation, NeoplasticHead and Neck NeoplasmsHEK293 CellsHumansLamininDNA, NeoplasmLAMC2 protein, humanLamininRNA, Long NoncodingTP63 protein, humanTranscription FactorsTumor Suppressor ProteinsZNF750 protein, human

Identifiers

PMID27819679
PMCPMC5415641

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.